药械审批先声再明 SIM06867月21日,先声药业旗下公司先声再明宣布,其自主研发的靶向FGFR2b的抗体偶联药物(ADC)SIM0686的临床试验申请(IND)已于近日获美国食品药品监督管理局(FDA)批准。远大医药 冠脉血管内冲击波系统7月22日,远大医药宣布用于治疗前列腺癌的全球创新在研放射性核素偶联药物(RDC)TLX591(177Lu-rosopatamab tetraxetan)加入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.